{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:55:20Z","timestamp":1781646920605,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Association for Research on Amyotrophic Lateral Sclerosis and other Motor Neurone Diseases","award":["Association for Research on Amyotrophic Lateral Sclerosis and other Motor Neurone Diseases"],"award-info":[{"award-number":["Association for Research on Amyotrophic Lateral Sclerosis and other Motor Neurone Diseases"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Most published economic studies about the burden of amyotrophic lateral sclerosis (ALS) have measured direct and indirect costs but did not consider the perspective of patients and families.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The French ALS patient association, ARSLA, contacted 15 ALS reference centers to recruit a random sample of ALS patients stratified by age and severity accepting to participate in a structured interview survey. The objective was to document the out-of-pocket (OOP) expenses associated with ALS for patients and families in 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty patients with a mean age 61.5 years (SD 12) participated in the survey. The average time since diagnosis was 28.9 months (SD 26.8). Most patients had disabling motor impairment, half of them (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926, 52%) affected 4 limbs, 27 (54%) required noninvasive respiratory support and 11 (22%) nutritional support. A proportion of 48% of patients or caregivers reported Out-of-Pocket (OOP) expenses for mobility equipment, 50% for home modifications, 40% for vehicle adaptations, and 54% for paying for paid caregivers. The mean annual OOP expenses was \u20ac7,764 (SD 9,776) in total of which home adaptations averaged \u20ac3,074 (SD 6,583), personal vehicle adaptation \u20ac2,774 (SD 5,239) and paid caregivers \u20ac1,279 (SD 3,351). The factors statistically significant for higher overall OOP expenses were the duration of ALS since diagnostic (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026) and use of paid caregivers (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). The support of family caregivers was almost systematic (88%), involving spouses (95.5%), children (22.7%) and relatives (13.6%). The mean annual loss of family income associated with professional change of patients and family caregivers was \u20ac7,633. When added to the OOP, the mean total annual economic burden was \u20ac15,397.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the full coverage of all ALS-related health expenditures within the French healthcare system and additional associated financial support, it remains a substantial economic burden for patients and families to manage this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04326-1","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:24:03Z","timestamp":1774970643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The economic burden of amyotrophic lateral sclerosis for patients and families: a survey on out-of-pocket expenses and income loss in France"],"prefix":"10.1186","volume":"21","author":[{"given":"Claude","family":"Desnuelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Couratier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Corcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thelma","family":"Arcelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Nevoret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Duburcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Baffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Turgeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"10","key":"4326_CR1","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918\u201329. https:\/\/doi.org\/10.1111\/ene.14393.","journal-title":"Eur J Neurol"},{"key":"4326_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/DNND.S135748","volume":"7","author":"M Hinchcliffe","year":"2017","unstructured":"Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61\u201370. https:\/\/doi.org\/10.2147\/DNND.S135748.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"1","key":"4326_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/0141076813511451","volume":"107","author":"D B\u00e4umer","year":"2014","unstructured":"B\u00e4umer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc Med. 2014;107(1):14\u201321. https:\/\/doi.org\/10.1177\/0141076813511451.","journal-title":"J R Soc Med"},{"issue":"3\u20134","key":"4326_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3109\/21678421.2014.999791","volume":"16","author":"J Oh","year":"2015","unstructured":"Oh J, An JW, Oh SI, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3\u20134):202\u20138. https:\/\/doi.org\/10.3109\/21678421.2014.999791.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"4326_CR5","doi-asserted-by":"publisher","first-page":"e001287","DOI":"10.1136\/rmdopen-2020-001287","volume":"6","author":"B Fautrel","year":"2020","unstructured":"Fautrel B, Boonen A, de Wit M, Grimm S, Joore M, Guillemin F. Cost assessment of health interventions and diseases. RMD Open. 2020;6(3):e001287. https:\/\/doi.org\/10.1136\/rmdopen-2020-001287.","journal-title":"RMD Open"},{"issue":"8","key":"4326_CR6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s10198-021-01328-7","volume":"22","author":"K Achtert","year":"2021","unstructured":"Achtert K, Kerkemeyer L. The economic burden of amyotrophic lateral sclerosis: a systematic review. Eur J Health Econ. 2021;22(8):1151\u201366. https:\/\/doi.org\/10.1007\/s10198-021-01328-7.","journal-title":"Eur J Health Econ"},{"issue":"1\u20132","key":"4326_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/21678421.2014.932384","volume":"16","author":"K Athanasakis","year":"2015","unstructured":"Athanasakis K, Kyriopoulos II, Sideris M, Rentzos M, Evdokimidis J, Kyriopoulos J. Investigating the economic burden of ALS in Greece: a cost-of-illness approach. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1\u20132):63\u20134. https:\/\/doi.org\/10.3109\/21678421.2014.932384.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"4326_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","volume":"257","author":"K Schepelmann","year":"2010","unstructured":"Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schr\u00f6der R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(1):15\u201323. https:\/\/doi.org\/10.1007\/s00415-009-5256-6.","journal-title":"J Neurol"},{"issue":"1","key":"4326_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13023-020-01413-9","volume":"15","author":"E Sch\u00f6nfelder","year":"2020","unstructured":"Sch\u00f6nfelder E, Osmanovic A, M\u00fcschen LH, Petri S, Schreiber-Katz O. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany. Orphanet J Rare Dis. 2020;15(1):149. https:\/\/doi.org\/10.1186\/s13023-020-01413-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"5\u20136","key":"4326_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/21678421.2023.2165947","volume":"24","author":"JD Berry","year":"2023","unstructured":"Berry JD, Blanchard M, Bonar K, Drane E, Murton M, Ploug U, et al. Epidemiology and economic burden of amyotrophic lateral sclerosis in the United States: a literature review. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(5\u20136):436\u201348. https:\/\/doi.org\/10.1080\/21678421.2023.2165947.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"4326_CR11","unstructured":"Fili\u00e8re nationale de sant\u00e9 maladies rares (FilSLAN). Scl\u00e9rose Lat\u00e9rale Amyotrophique et maladies du neurone moteur.https:\/\/portail-sla.fr\/filiere-filslan\/. [Accessed 27 October 2025]."},{"key":"4326_CR12","unstructured":"IRDES Glossaire franco-anglais des termes en \u00e9conomie de la sant\u00e9. (Novembre 2024) https:\/\/www.irdes.fr\/recherche\/ouvrages\/005-glossaire-franco-anglais-des-termes-en-economie-de-la-sante.pdf. [Accessed 27 October 2025]."},{"issue":"1\u20132","key":"4326_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/21678421.2016.1241280","volume":"18","author":"R Vasta","year":"2017","unstructured":"Vasta R, Boum\u00e9diene F, Couratier P, Nicol M, Nicoletti A, Preux PM, et al. Fralim Consortium. Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1\u20132):24\u201331. https:\/\/doi.org\/10.1080\/21678421.2016.1241280.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"4326_CR14","doi-asserted-by":"publisher","first-page":"120764","DOI":"10.1016\/j.jns.2023.120764","volume":"452","author":"K Stenson","year":"2023","unstructured":"Stenson K, O\u2019Callaghan L, Mellor J, Wright J, Gibson G, Earl L, et al. Healthcare resource utilization at different stages of amyotrophic lateral sclerosis: Results from a real-world survey. J Neurol Sci. 2023;452:120764. https:\/\/doi.org\/10.1016\/j.jns.2023.120764.","journal-title":"J Neurol Sci"},{"key":"4326_CR15","unstructured":"Centre des liaisons europ\u00e9ennes et internationales de s\u00e9curit\u00e9 sociale. The French Social Security System IV - Family benefits. Available at https:\/\/www.cleiss.fr\/docs\/regimes\/regime_france\/an_4.html. [Accessed 27 October 2025]."},{"key":"4326_CR16","unstructured":"Valdes B\u00e9atrice. (2022). ESPN Thematic report on social protection for people with disabilities \u2013 France, European Social Policy Network (ESPN), Brussels: European Commission. Available at https:\/\/hal.science\/hal-04444015v1\/file\/ESPN_FR_SocialProtectionDisability_2022.pdf. [Accessed 27 October 2025]."},{"issue":"5\u20136","key":"4326_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/21678421.2017.1306566","volume":"18","author":"S Kab","year":"2017","unstructured":"Kab S, Moisan F, Preux PM, Marin B, Elbaz A. Nationwide incidence of motor neuron disease using the French health insurance information system database. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5\u20136):426\u201333. https:\/\/doi.org\/10.1080\/21678421.2017.1306566.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"4326_CR18","doi-asserted-by":"crossref","unstructured":"Desnuelle C, Couratier P, Corcia P, Duburcq A, Torreton E, Baffert S, Nevoret C, Turgeman S. Treatment pathway, healthcare resource utilization and direct cost of ALS in France: a nationwide claims database study. Rev Neurol 2026 (in Press).","DOI":"10.1016\/j.neurol.2026.02.159"},{"key":"4326_CR19","unstructured":"OECD Health Statistics 2023, OECD National accounts database. Out-of-pocket spending as share of final household consumption. 2021. Available at https:\/\/www.oecd.org\/en\/publications\/2023\/11\/health-at-a-glance-2023_e04f8239\/full-report\/financial-hardship-and-out-of-pocket-expenditure_01896d0f.html#indicator-d1e23053-0631b961c7. [Accessed 27 October 2025]."},{"key":"4326_CR20","unstructured":"European Commission: Directorate-general for employment, social affairs and inclusion, European Social Policy Network (ESPN), Baptista I, Marlier E, Publications Office of the European Union. Social protection for people with disabilities \u2013 An analysis of policies in 35 countries. 2022. Available at https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/ef1a0223-9e1e-11ed-b508-01aa75ed71a1\/language-en. [Accessed 27 October 2025]."},{"issue":"5\u20136","key":"4326_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3109\/21678421.2014.932382","volume":"15","author":"M Gladman","year":"2014","unstructured":"Gladman M, Dharamshi C, Zinman L. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5\u20136):426\u201332. https:\/\/doi.org\/10.3109\/21678421.2014.932382.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"6","key":"4326_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2165\/00019053-199304060-00006","volume":"4","author":"MA Koopmanschap","year":"1993","unstructured":"Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. PharmacoEconomics. 1993;4(6):446\u201354. https:\/\/doi.org\/10.2165\/00019053-199304060-00006.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"4326_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mus.23942","volume":"49","author":"J Larkindale","year":"2014","unstructured":"Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431\u20138. https:\/\/doi.org\/10.1002\/mus.23942.","journal-title":"Muscle Nerve"},{"key":"4326_CR24","unstructured":"Muscular, Dystrophy: Cost of amyotrophic lateral sclerosis, muscular dystrophy, and spinal muscular atrophy in the United States. 2012. Available at https:\/\/www.mda.org\/sites\/default\/files\/Cost_Illness_Report.pdf. [Accessed 27 October 2025]."},{"issue":"4","key":"4326_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/17482960802430781","volume":"10","author":"J L\u00f3pez-Bastida","year":"2009","unstructured":"L\u00f3pez-Bastida J, Perestelo-P\u00e9rez L, Mont\u00f3n-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009;10(4):237\u201343. https:\/\/doi.org\/10.1080\/17482960802430781.","journal-title":"Amyotroph Lateral Scler"},{"issue":"1\u20132","key":"4326_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0022-510x(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1\u20132):13\u201321. https:\/\/doi.org\/10.1016\/s0022-510x(99)00210-5.","journal-title":"J Neurol Sci"},{"issue":"5","key":"4326_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.neurol.2018.09.017","volume":"175","author":"P Corcia","year":"2019","unstructured":"Corcia P, Beltran S, Lautrette G, Bakkouche S, Couratier P. Staging amyotrophic lateral sclerosis: A new focus on progression. Rev Neurol (Paris). 2019;175(5):277\u201382. https:\/\/doi.org\/10.1016\/j.neurol.2018.09.017.","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"4326_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jnnp-2013-306589","volume":"86","author":"A Chi\u00f2","year":"2015","unstructured":"Chi\u00f2 A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38\u201344. https:\/\/doi.org\/10.1136\/jnnp-2013-306589. Epub 2013 Dec 13. PMID: 24336810.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04326-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04326-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04326-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:15:46Z","timestamp":1781644546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04326-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4326"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04326-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the CESREES (Comit\u00e9 \u00e9thique et scientifique pour les recherches, les \u00e9tudes et les \u00e9valuations dans le domaine de la sant\u00e9), the National Data Protection Authority CNIL (Commission Nationale de l\u2019Informatique et des Libert\u00e9s) (reference PHT\/POU\/ AR2311493, 01\/08\/2023). According to CESREES and CNIL, a written informed consent was required for the study. The research complies with the guidelines for human studies and was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"CD is vice-President of ARSLA and no COI to declare. P.Corcia and P.Couratier have no COI to declare. ST is an employee of ARSLA, which supported this study. SB, CN, ET and AD are CEMKA employees, who received grants from ARSLA to conduct this analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}